About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68827 record(s)
Req # A-2023-000820
With respect to the Abbreviated New Drug Submission (ANDS) for liraglutide accepted into review on August 2017, copies of any Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W), a NON-Withdrawal (NON-W) or sponsor…Organization: Health Canada
February 2024
Req # A-2023-000965
The exact milligram amount of every ingredient in the Natural health products: Zonnic Polar Mint ; Zonnic Berry Frost ; Zonnic Chill Mint ; Zonnic Cranberry Fizz ; Zonnic Tropic Breeze Natural Product Number (NPN): 80125630.Organization: Health Canada
February 2024
Req # A-2023-000983
Current standing/ stop sale requests for ELEVAI EXOSOMES distributed by Evolve Medical.Organization: Health Canada
February 2024
Req # A-2023-001021
The Section 1.0.7 “Note to the Reviewer” from the generic manufacturer of the Liraglutide Abbreviated New Drug Submission (ANDS) which appears on the Generic Submissions Under Review (GSUR) List.Organization: Health Canada
February 2024
Req # A-2023-001028
All correspondence or other records relating to any pre-submission or pre-application meeting(s) requested by a sponsor in respect of a drug submission/application for a product containing the medicinal ingredient semaglutide.Organization: Health Canada
February 2024
Req # A-2023-001029
All correspondence in respect of the liraglutide submission which was removed from the Generic Submissions Under Review (GSUR) List some time between March 15, 2022 and December 13, 2022 between Health Canada and the company (sponsor) who submitted…Organization: Health Canada
February 2024
Req # A-2023-001047
A Health Canada Compliance and Enforcement Inspection Report on the Cannabis Industry reported, for 2018-19, 32 referrals from Health Canada to the Royal Canadian Mounted Police (RCMP) for action. The names of the 32 companies and/or promotions…Organization: Health Canada
February 2024
Req # A-2023-001083
Information regarding product name, dosage form and strength of Carbidopa, levodopa generic submissions under review. This product listed under Generic Submissions Under Review list dated 2023-10-19.Organization: Health Canada
February 2024
Req # A-2023-001153
A report/speadsheet showing the total number of consultant hired and all corresponding costs, broken down by department/agency and calendar year (2015 - 2023).Organization: Health Canada
February 2024
Req # A-2023-001158
All information included in the submission and review of Natural Product Number (NPN) 80059723 Berberine/Berberine 500 mg.Organization: Health Canada
February 2024